PTGS2 and lung carcinoma: In humans, a case-control study showed that use of selective COX-2 inhibitors, among which celecoxib, reduced the lung cancer risk [12], and a trial of celecoxib in former smokers decreased the bronchial Ki-67 labeling index and reduced lung nodules on computed tomography [13].